Who is the new CEO of BCAL Diagnostics (ASX:BDX)?

BCAL Diagnostics has appointed Anne-Louise (Annie) Arnett as Chief Executive Officer, effective 1 June 2026. Arnett brings over 25 years of experience in the medical technology sector, specifically in launching diagnostic products and managing regulated portfolios in Australian and international markets.

Why is BCAL Diagnostics (ASX:BDX) changing its leadership now?

The appointment of Anne-Louise Arnett marks a strategic pivot from scientific development toward a commercial-first roadmap. As the company prepares to bring its early-cancer detection products to market and expand globally, it requires a CEO with a proven track record in commercialisation and international regulatory navigation.

What happens to the previous CEO of BCAL Diagnostics?

Shane Ryan, the outgoing CEO, will transition to the role of Director of Clinical Affairs, Breast Cancer. This move is designed to ensure scientific continuity for BCAL’s flagship breast programme while allowing the new CEO to focus exclusively on the broader commercial and operational agenda.

What are the key products in the BCAL Diagnostics (ASX:BDX) pipeline?

BCAL is currently focusing on the clinical and commercial rollout of BREASTESTplus and its multi-cancer early detection platform. The company's goal is to transition these tools from the development phase to widespread clinical availability both in Australia and overseas.

BCAL Diagnostics appoints Anne-Louise Arnett as new CEO

Written by Heidi Cuthbert Published May. 11 2026Last Updated May. 11 2026

BCAL Diagnostics (ASX:BDX), an Australian healthcare innovator specialising in early-stage cancer detection, appointed Anne-Louise Arnett as its CEO.

Effective June 1, Arnett's appointment marks a pivot for the company as it shifts focus towards accelerating its commercial roadmap and expanding its international footprint.

Bringing over 25 years of senior leadership experience within the medical technology sector, Arnett possesses a proven track record of launching diagnostic products and navigating complex regulated portfolios across both domestic and global markets.

Her expertise is expected to be instrumental as BCAL prepares to transition its core pipeline—including the BREASTESTplus and the multi-cancer early detection platform—from development to widespread clinical and commercial availability.

The transition also includes key shifts within the executive board. Shane Ryan, the outgoing CEO who was pivotal in establishing the company’s scientific foundations, will transition into the role of Director of Clinical Affairs, Breast Cancer.

The move ensures continuity for BCAL’s flagship breast programme while allowing Ms Arnett to spearhead the broader commercial agenda.

Executive Chair Jayne Shaw will transition to non-executive chair on July 1, reflecting the natural evolution of the company’s governance.

At the time of reporting, BCAL Diagnostics’ share price was $0.076.